Help protect against another heart attack

After a heart attack, your risk for another one remains increased, permanently.1

A heart attack is also called acute coronary syndrome or ACS.

One in Five Patients
One in Five Patients

In the first year after a heart attack, up to 1 in 5 patients is at risk for a recurrent CV event or death1,2*

Nearly 50% Second Heart Attack Occurs at Another Location in Your Coronary Arteries
Nearly 50% Second Heart Attack Occurs at Another Location in Your Coronary Arteries

If you had a stent put in, your risk is still high. Nearly half of second heart attacks occur at another location in the arteries of your heart—not where you had your stent put in3‡

Key risk factors for another heart attack4

Patient Age Patient age

Medical HistoryMedical history

Health Condition Health conditions

Severity of Heart AttackSeverity of heart attack

Do everything you can to help reduce your risk, including taking medicines as prescribed by your cardiologist.

*The APOLLO HELICON analysis was a retrospective cohort study that included 108,315 patients from a National Swedish registry with a primary diagnosis of acute MI between July 2006 and June 2011. The primary end point was risk of nonfatal MI, nonfatal stroke, or CV death. The cumulative 1-year incidence of the primary end point was 18.3%.1


Data from 6 pooled National Heart, Lung, and Blood Institute (NHLBI) databases in patients ≥45 years of age after their first MI. Incidence in different populations may be higher or lower. AHA Heart Disease and Stroke Statistics 2018 update, a publication of statistics on heart disease, stroke, other vascular disease, and their risk factors from the American Heart Association (AHA), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and other government agencies.2


The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study was conducted at 37 sites in the United States and Europe. 697 patients with ACS underwent 3-vessel coronary angiography and grayscale and radiofrequency intravascular ultrasonographic imaging after PCI. Median follow-up was 3.4 years, and 96% of patients underwent stent implantation. Subsequent major adverse CV events (death from cardiac causes, cardiac arrest, MI, or rehospitalization due to unstable or progressive angina) were adjudicated to be related to either originally treated (culprit) lesions or untreated (nonculprit) lesions.3


Risk after a heart attack is high.


Two-year rate: Death, MI, or stroke in patients with STEMI vs NSTEMI4

Alert Icon

Whether you had a heart attack classified as STEMI or NSTEMI, you are at high risk of having another one
Risk Post MI
Risk Post MI
  • Cumulative incidence of death, MI, or stroke in STEMI vs NSTEMI: within the first 90 days: 7.9% vs 8.1%; 90 days to 2 years: 15.2% vs 21.5%; Post discharge to 2 years: 21.9% vs 27.9%.

*The ACTION Registry–Get With the Guidelines (GWTG) is the largest nationwide registry of acute MI in the United States. Patients (N=46,199) were ≥65 years, who presented with either STEMI or NSTEMI to 504 participating hospitals from January 2, 2007 to December 31, 2010, underwent coronary angiography, found to have significant CAD with at least one coronary stenosis in a major epicardial vessel >50%, and had been enrolled in Medicare fee-for-service Parts A and B plans for at least 1 year prior to the index MI hospitalization. Patients who survived the index hospitalization and were discharged to home were included. From hospital discharge through 2 years, the cumulative incidence rates for the composite end point were lower among patients with STEMI compared to those with NSTEMI.

Long-term risk one year after a heart attack

Once you’ve had a heart attack, you remain at risk for having another. Permanently.

Three Out of Four Patients
Three Out of Four Patients

If you have 2 or more risk factors, your risk is even higher. 3 out of 4 patients who had another heart attack had 2 or more risk factors5

Risk factors included5
  • Chronic kidney disease (eGFR 15-89 mL/min/1.73 m2)
  • Multivessel coronary artery disease
  • Diabetes mellitus managed with antidiabetic medicine
  • Age ≥65 years
  • Anemia
  • Chronic lung disease
  • Prior MI (>3 months prior)
  • Peripheral artery disease
  • Left ventricular ejection fraction <40%
  • Cardiac arrest or cardiogenic shock during MI hospitalization

Questions to review with your ACS patients

Review these important topics with patients taking BRILINTA.
  • Do your patients understand their risk of having another heart attack?
  • Do your patients understand why you've chosen their treatment regimen, including their oral antiplatelet?
  • Are your patients aware of how to take their treatment regimen, including their oral antiplatelet?
  • Do they understand how long they may need to take medications, including their oral antiplatelet, and potential reasons for discontinuation?
  • Do they know that it’s important to stay on their treatments for as long as their doctor recommends?
  • Are they aware of what lifestyle modifications they need to make, such as diet, exercise, cardiac rehabilitation, and management of comorbidities?
  • Are your patients aware of the possible side effects of their medications, including their oral antiplatelet?
  • Do your patients understand the importance of talking to other physicians about the medications they are taking, including their oral antiplatelet?


ACS=acute coronary syndrome; CAD=coronary artery disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; MI=myocardial infarction; NSTEMI=non–ST-elevation myocardial infarction; STEMI=ST-elevation myocardial infarction.

  1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163-1170.
  2. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596.
  3. Stone GW, Maehara A, Lansky AJ, et al; for the PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226-235.
  4. Vora AN, Wang TY, Hellkamp AS, et al. Differences in short- and long-term outcomes among older patients with ST-elevation versus non-ST-elevation myocardial infarction with angiographically proven coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016;9(5):513-522.
  5. Spertus J, Bhandary D, Fonseca E, et al. Contemporary incidence of recurrent cardiovascular events 1 to 3 years after myocardial infarction: longitudinal US analysis from NCDR registries linked with all-payer claims database. Presented at: The American College of Cardiology 67th Annual Scientific Session & Expo; Orlando, FL; March 12, 2018.